N-[4-[3-methyl-4-(1-methylbenzimidazol-5-yl)oxyanilino]quinazolin-6-yl]prop-2-enamide | 937265-22-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-[4-[3-methyl-4-(1-methylbenzimidazol-5-yl)oxyanilino]quinazolin-6-yl]prop-2-enamide
• CAS: 937265-22-0
• 化学式: C₂₆H₂₂N₆O₂
• 分子量: 450.5
• InChiKey: HUFJETRINOEBJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  94
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
  申请人：ARRAY BIOPHARMA, INC.

  公开号：US20140023643A1

  公开（公告）日：2014-01-23

  This invention provides compounds of Formula I wherein B, G, A, E, R 1 , R 2 , R 3 , m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

  本发明提供了I式化合物，其中B、G、A、E、R1、R2、R3、m和n如本文所定义，它们可用作I型受体酪氨酸激酶抑制剂，并且在哺乳动物的增殖过度疾病治疗中使用的方法。
• N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases
  申请人：Lyssikatos Joseph P.

  公开号：US20110034689A1

  公开（公告）日：2011-02-10

  This invention provides compounds of Formula I wherein B, G, A, E, R 1 , R 2 , R 3 , m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

  本发明提供了式I中的化合物，其中B、G、A、E、R1、R2、R3、m和n的定义如本文所述，这些化合物可用作I型受体酪氨酸激酶抑制剂，并且可以用于哺乳动物的增殖过度性疾病的治疗方法。
• N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
  申请人：ARRAY BIOPHARMA, INC.

  公开号：US10780073B2

  公开（公告）日：2020-09-22

  This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

  本发明提供了式 I 的化合物 其中 B、G、A、E、R1、R2、R3、m 和 n 如本文所定义，可用作 I 型受体酪氨酸激酶抑制剂，并可用于治疗哺乳动物的过度增殖性疾病。
• N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
  申请人：Array BioPharma Inc.

  公开号：US20210008023A1

  公开（公告）日：2021-01-14

  This invention provides compounds of Formula I wherein B, G, A, E, R 1 , R 3 , R 4 , m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
• [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20210332054A1

  公开（公告）日：2021-10-28

  The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R 1 , R 2 , R 3 and R 4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.